JPRN-UMIN000001276已完成未知
Japan Home versus Office Measurement Evaluation for Heart Rate study - J-HOME-HR study
Department of Clinical Pharmacology and Therapeutics, Tohoku University Graduate School of Pharmaceutical Sciences and Medicine0 个研究点目标入组 50 人开始时间: 2008年8月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Taking beta blockers, anti arrhythmic drug, cardio tonic, or bradycardiac drug within a month, 2.Contraindications or hypersensitivity to beta blockers use, 3.Pulmonary disease, severe diabetes mellitus, or hyperthyroidism, 4.Malignant hypertension, 5.Secondary hypertension, 6.Not available for informed consent, 7.Participating other intervention trials, 8.Severe complications leading to stop this study, 9.Other inappropriate conditions judged by each physician
研究者
相似试验
已完成
不适用
A survey for Japanese Office workers to Assess Stress Issues and Sleep problemsHigh-stress workersJPRN-UMIN000045528Department of Neuropsychiatry, Keio University, School of Medicine130
招募中
不适用
Japanese observational study to evaluate the accuracy of preoperative imaging diagnosis for lateral pelvic lymph node metastasis in rectal cancer (JCOG1410-A, JUPITER study)Rectal cancer with rectal resection and lateral pelvic lymph node dissectionJPRN-UMIN000016909Japan Clinical Oncology Group (JCOG)550
已完成
不适用
Assessment of quality of life using Japanese version of Bladder Cancer Index questionnaire in patients before and after radical cystectomy : a multicenter prospective observational studyBladder cancerJPRN-UMIN000039538Hokkaido University Graduate School of Medicine200
未知
1 期
A Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naive Patients With Castration-Resistant Prostate CancerChemotherapy-naive castration-resistant prostate cancerJPRN-jRCT2080221877Takeda Pharmaceutical Company Limited72
进行中（未招募）
1 期
Study to find out the effects and fate of treatment with Orteronel plus prednisone in Japanese and non Japanese people that have not recieved cancer therapy for prostate cancer.progressive castration-resistant prostate cancer.MedDRA version: 14.1Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-001539-30-NLMillennium Pharmaceuticals, Inc.144